<DOC>
	<DOC>NCT01122368</DOC>
	<brief_summary>Subjects with intra-abdominal infection requiring surgery and Intensive Care Unit stay will be treated early with micafungin or placebo to determine the incidence and time to confirmation of fungal infection.</brief_summary>
	<brief_title>A Study to Evaluate Pre-emptive Treatment for Invasive Candidiasis in High Risk Surgical Subjects</brief_title>
	<detailed_description>Subjects will be assessed at the following visits: - Baseline (after surgery, prior to randomization) - End of Treatment (EOT) visit (EOT is defined as: requires alternative antifungal, sufficient improvement of surgical condition, confirmed fungal infection or death) - End of Study visit (28 days after the EOT visit) - Long-term Follow up visit (90 days after the EOT visit)</detailed_description>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Candidiasis, Invasive</mesh_term>
	<mesh_term>Micafungin</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<criteria>Intraabdominal infection requiring surgery and Intensive Care Unit stay If Community Acquired IntraAbdominal Infection, at least 72 hours (but not more than 120 hours) of Intensive Care Unit stay, counted from the end of surgery, and a further expected duration of Intensive Care Unit stay of ≥ 48 hours If Nosocomial IntraAbdominal Infection, duration of Intensive Care Unit stay ≤ 48 hours, counted from the end of surgery, and a further expected duration of Intensive Care Unit stay of ≥ 48 hours Female subject of childbearing potential must have a negative urine or serum pregnancy test prior to randomization and must agree to maintain highly effective birth control during the study Acute pancreatitis Neutropenia (ANC &lt;1,000/mm3) at the time of randomization Infected intraperitoneal dialysis Patients undergoing solid organ transplantation Documented invasive candidiasis at the time of randomization Expected survival &lt; 48 hours Any systemically active antifungal within 14 days prior to administration of the study drug Allergy, hypersensitivity, or any serious reaction to an echinocandin antifungal or any of the study drug excipients Currently receiving and/or has taken an investigational drug within 28 days prior to randomization Pregnant woman or breastfeeding mother 'Do Not Resuscitate' order</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Micafungin</keyword>
	<keyword>mycoses</keyword>
	<keyword>invasive fungal infection</keyword>
	<keyword>intra-abdominal surgery</keyword>
	<keyword>intra-abdominal infection</keyword>
</DOC>